A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy
Condition: Crohn's Disease Interventions: Drug: Upadacitinib; Drug: Placebo for Upadacitinib Sponsor: AbbVie Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials